September 23, 2013
1 min read

Aerie Pharmaceuticals files for proposed initial public offering

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Aerie Pharmaceuticals has filed an S-1 registration statement with the U.S. Securities and Exchange Commission involving a proposed initial public offering of common stock, according to a company news release.

The price range and number of shares to be sold on behalf of Aerie, a clinical-stage company focused on therapies to treat patients with glaucoma and other eye diseases, have not been determined, the release said.

AR-13324, the company’s lead product candidate, is a once-daily eye drop intended to reduce IOP in patients with glaucoma or ocular hypertension.

Its PG324 product candidate is a fixed combination of AR-13324 and latanoprost in a single eye drop designed to lower IOP by simultaneously reducing fluid inflow and opening both of the eye’s fluid drains.

Aerie intends to trade its stock on the NASDAQ global market under the ticker symbol AERI.